SurModics/$SRDX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About SurModics

Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.

Ticker

$SRDX
Primary listing

Industry

Health Care Equipment & Supplies

Employees

389

ISIN

US8688731004

SurModics Metrics

BasicAdvanced
$416M
-
-$1.40
1.30
-

What the Analysts think about SurModics

Analyst ratings (Buy, Hold, Sell) for SurModics stock.

Bulls say / Bears say

Surmodics secured a group purchasing agreement with Premier, Inc., granting access to over 4,350 U.S. hospitals and 300,000 other providers, potentially expanding its market reach for thrombectomy products. (stocktitan.net)
The company reported a 10% year-over-year increase in Medical Device revenue (excluding the SurVeil DCB license fee) in Q3 FY2024, indicating strong organic growth in its core segment. (stocktitan.net)
Surmodics announced the commercial release of the Pounce™ XL Thrombectomy System, designed for rapid non-surgical clot removal in iliac and femoral arteries, showcasing its commitment to innovative product development. (stocktitan.net)
The U.S. Federal Trade Commission sued to block Surmodics' acquisition by private equity firm GTCR, citing concerns over reduced competition and potential increases in healthcare costs. (reuters.com)
In Q2 FY2025, Surmodics reported a 12.1% year-over-year decline in total revenues, missing consensus estimates by 8.7%, raising concerns about its financial performance. (finviz.com)
Analysts have initiated coverage on Surmodics with a 'hold' rating, reflecting cautious sentiment and potential uncertainty about the company's future growth prospects. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.

SurModics Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

SurModics Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SRDX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs